Open AccessChitin Analog AVR-25 Prevents Experimental Bronchopulmonary Dysplasia
Author(s) -
Pragnya Das,
Suchismita Acharya,
Dilip Shah,
Beamon Agarwal,
Varsha M. Prahaladan,
Vineet Bhandari
Publication year - 2020
Publication title -
journal of pediatric intensive care
Language(s) - English
Resource type - Journals
eISSN - 2146-4618
pISSN - 2146-4626
DOI - 10.1055/s-0040-1709994
Subject(s) - bronchopulmonary dysplasia , medicine , hyperoxia , inflammation , lung , immune system , dysplasia , immunology , pregnancy , genetics , biology , gestational age
Infants born extremely preterm are at a high risk of developing bronchopulmonary dysplasia (BPD) which is characterized by large, simplified alveoli, increased inflammation, disrupted and dysregulated vasculogenesis, decreased cell proliferation, and increased cell death in the lungs. Due to lack of specific drug treatments to combat this condition, BPD and its long-term complications have taken a significant toll of healthcare resources. AVR-25, a novel immune modulator experimental compound, was able to partially recover the pulmonary phenotype in the hyperoxia-induced experimental mouse model of BPD. We anticipate that AVR-25 will have therapeutic potential for managing human BPD.